3, 4, 5-triamino-1, 2, 4-triazolium 5-nitrotetrazolate (2) was synthesized in high yield from 3, 4, 5-triamino-1, 2, 4-triazole (guanazine) (1) and ammonium 5-nitrotetrazolate. The new compound (2) was characterized by vibrational (IR and Raman) and multinuclear NMR spectroscopy (^1H, ^13C, ^15N), elemental analysis and single crystal X-ray diffraction (triclinic, P(-1), a = 7.194(5), b = 8.215(5), c = 8.668(5) nm, alpha = 75.307(5), β = 70.054(5), gama = 68.104(5)°, V = 442.1(5) nm^3, Z = 2, ρ = 1.722 g cm^-1, R_1= 0.0519 [F > 4σ (F)], wR_2 (all data) = 0.1154). The ^15N NMR spectrum and X-ray crystal structure (triclinic, P-1, a = 5.578(5), b = 6.166(5), c = 7.395(5) nm, alpha = 114.485(5)°, β = 90.810(5)°, gama = 97.846(5)°, V = 228.6(3) nm^3, Z = 2, ρ = 1.658 g cm^-1, R_1 = 0.0460 [F > 4σ (F)], wR_2 (all data) = 0.1153) of 1 were also determined.

In this study we investigated the association of the interleukin-1 receptor antagonist gene variable number tandem repeat (IL1RN VNTR) polymorphism and of the inhibitor of kappa B-like protein (IKBL) gene polymorphism with myocardial infarction (MI) in a group of patients with type 2 diabetes. The IL1RN VNTR and the IKBL+ 738T > C gene polymorphisms were tested in 374 Caucasians: 151 cases with MI and 223 subjects with no history of coronary artery disease. The IL1RN VNTR polymorphism was not a risk factor for MI in Caucasians with type 2 diabetes (genotype 22 vs. the rest: odds ratio (OR) 1.6; 95% confidence interval (CI) = 0.8-3.5; p = 0.2). We also failed to demonstrate that IKBL+ 738T > C gene polymorphism was associated with MI in patients with type 2 diabetes (OR = 0.9; 95% CI = 0.3-2.6; p = 0.9). We provide evidence that the IL1RN VNTR and the IKBL + 738T > C gene polymorphisms are not risk factors for MI in Caucasians with type 2 diabetes.